Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab in chronic cluster headache
NCT02438826Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2015
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of galcanezumab in Cluster Headache (CH), sponsored by Eli Lilly and Company. Started Jun 2015; status: completed.
02
Drugs
galcanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NCT02438826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02438826.